Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study

被引:12
|
作者
Choi, Soojeong [1 ]
Lee, Young Jae [2 ]
Jeong, Jae Ho [3 ]
Jung, Jinhong [4 ]
Lee, Jong Won [1 ]
Kim, Hee Jeong [1 ]
Ko, Beom Seok [1 ]
Son, Byung Ho [1 ]
Ahn, Sei Hyun [1 ]
Lee, Yura [1 ,5 ]
Chung, Il Yong [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Obstet & Gynecol, Kangnung, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med Informat, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
breast neoplasms; dilatation and curettage; gynecological examination; tamoxifen; endometrial neoplasms; SURGICAL ADJUVANT BREAST; ENDOCRINE THERAPY; LONG-TERM; WOMEN; PREVENTION; SOCIETY;
D O I
10.3389/fonc.2021.636378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors has not yet been fully assessed. This study aimed to investigate the risk of developing endometrial cancer and the frequencies of gynecological examinations in young breast cancer survivors taking TAM in South Korea. Methods A nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment Service claims data. Kaplan-Meier analyses and log-rank tests were used to assess the probability of endometrial cancer, benign endometrial conditions, and the probability of invasive endometrial procedure. To analyze the risk of endometrial cancer and benign endometrial conditions, we used a multivariable Cox proportional hazards regression model. Results Between 2010 and 2015, 60,545 newly diagnosed female breast cancer survivors were included. The total person-years were 256,099 and 140 (0.23%) patients developed endometrial cancer during the study period. In breast cancer survivors aged >= 60 years [hazard ratio (HR), 5.037; 95% confidence interval (CI), 2.185-11.613], 50-59 years (HR, 4.343; 95% CI, 2.122-8.891), and 40-49 years (HR, 2.121; 95% CI, 1.068-4.213), TAM was associated with an increased risk of endometrial cancer. In subjects aged below 40 years, TAM did not significantly increase the risk of endometrial cancer. However, among the TAM subgroups, breast cancer survivors aged below 40 years [1.61 per 1,000 person-years (PY); HR, 12.460; 95% CI, 2.698-57.522] and aged 40-49 years (2.22 per 1,000 PY; HR, 9.667; 95% CI, 4.966-18.819) with TAM-related endometrial diseases showed significantly increased risks of endometrial cancer. Among the TAM subgroup with benign endometrial conditions, the ratios of the frequency of invasive diagnostic procedures to the incidence of endometrial cancer were higher in subjects under 40 than subjects aged 60 or more. Conclusion Young breast cancer survivors with TAM-related benign endometrial diseases are at a higher risk of developing endometrial cancer. Gynecological surveillance should be tailored to the risk of endometrial cancer in young breast cancer survivors to improve the early detection of endometrial cancer and avoid unnecessary invasive procedures.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment
    Neri, F.
    Maggino, T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 30 (04) : 357 - 360
  • [22] Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients
    Cohen, I
    Bernheim, J
    Azaria, R
    Tepper, R
    Sharony, R
    Beyth, Y
    GYNECOLOGIC ONCOLOGY, 1999, 75 (01) : 136 - 141
  • [23] Endometrial cancer after tamoxifen treatment: A descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer
    PetersEngl, C
    Medl, M
    Danmayr, E
    Mirau, M
    Alth, G
    Leodolter, S
    ANTICANCER RESEARCH, 1996, 16 (5B) : 3241 - 3246
  • [24] The Value of Transvaginal Ultrasonography in the Endometrial Evaluation of Breast Cancer Patients Using Tamoxifen
    Kazerooni, Talieh
    Ghaffarpasand, Fariborz
    Mosalaei, Ahmad
    Kazeroonip, Yasaman
    MEDICAL PRINCIPLES AND PRACTICE, 2010, 19 (03) : 222 - 227
  • [25] The Prescription Pattern of Chinese Herbal Products That Contain Dang-Qui and Risk of Endometrial Cancer among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study
    Wu, Chien-Tung
    Lai, Jung-Nien
    Tsai, Yueh-Ting
    PLOS ONE, 2014, 9 (12):
  • [26] Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen
    Zhu, Yunshan
    Yang, Jianhua
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (09) : 1411 - 1414
  • [27] Endometrial abnormalities in breast cancer patients with tamoxifen therapy
    Prevedourakis, C
    Makris, N
    Xygakis, A
    Dachlythras, M
    Michalas, S
    GYNAECOLOGICAL ENDOSCOPY, 2000, 9 (01) : 23 - 26
  • [29] Pregnancy duration and endometrial cancer risk: nationwide cohort study
    Husby, Anders
    Wohlfahrt, Jan
    Melbye, Mads
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 366
  • [30] Risk factors for second primary cancer in a prospective cohort of endometrial cancer survivors: an Alberta Endometrial Cancer Cohort Study
    Kokts-Porietis, Renee L.
    O'Sullivan, Dylan E.
    Nelson, Gregg
    Courneya, Kerry S.
    Cook, Linda S.
    Friedenreich, Christine M.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2024, : 1701 - 1711